{"created":"2024-11-29T09:49:46.989081+00:00","id":2001839,"links":{},"metadata":{"_buckets":{"deposit":"0cd513bb-b3d7-4628-ac09-c06a870c10c5"},"_deposit":{"created_by":8,"id":"2001839","owners":[8],"pid":{"revision_id":0,"type":"depid","value":"2001839"},"status":"published"},"_oai":{"id":"oai:fmu.repo.nii.ac.jp:02001839","sets":["1732778801467:1732778962699:1732873412714"]},"author_link":[],"item_1617186331708":{"attribute_name":"Title","attribute_value_mlt":[{"subitem_title":"Suppression of advanced glycation and lipoxidation end products by Angiotensin ii type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension","subitem_title_language":"en"}]},"item_1617186419668":{"attribute_name":"Creator","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ono, Yoshiaki","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Mizuno, Kenji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Takahashi, Michihiko","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Miura, Yukio","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Watanabe, Tsuyoshi","creatorNameLang":"en"}]}]},"item_1617186499011":{"attribute_name":"Rights","attribute_value_mlt":[{"subitem_rights":"© 2013 The Fukushima Society of Medical Science","subitem_rights_language":"en"}]},"item_1617186609386":{"attribute_name":"Subject","attribute_value_mlt":[{"subitem_subject":"type 2 diabetes mellitus (DM)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"essential hypertension (EH)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"candesartan","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"advanced glycation end products (AGEs)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"advanced lipoxidation endproducts (ALEs)","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"microalbuminuria","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"oxidative stress","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_1617186626617":{"attribute_name":"Description","attribute_value_mlt":[{"subitem_description":"Objective: This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH).Methods: Urinary excretion of pyrraline (PR), pentosidine (PT), acrolein (AC), and 8-hydroxy-2'-deoxyguanosine (8-OH-dG) and microalbuminuria were assessed in patients with DM complicated by EH who were treated with candesartan 4 mg/day for 3 months.Results: In a total of 25 patients urinary excretion of PR (nmol/g· cr), PT (pmol/g· cr), and 8-OH-dG (ng/mg· cr) was significantly (all P < 0.05) decreased from (mean ± SEM) 11.9 ± 1.9, 30.6 ± 2.4, and 7.9 ± 0.6, respectively, at baseline to 8.4 ± 1.4, 27.1 ± 2.0, and 6.9 ± 0.6, respectively, at 3 months. Meanwhile, excretion of AC was unaltered from 209.6 ± 40.0 to 189 ± 24.8 nmol/mgcr (P = NS). Urinary albumin excretion was significantly (P < 0.05) reduced from 27.7 ± 4.6 to 14.1 ± 1.1 mg/g· cr. There were weak but statistically significant positive correlations between the change of urinary 8-OH-dG excretion and that of albumin (r = 0.414; P < 0.05) and change of hemoglobin (Hb) A1c (r = 0.45; P < 0.05).Conclusion: Candesartan exerts protective effect(s) on the cardiovascular system by suppression of oxidative stress-mainly through inhibiting production of advanced glycation end products (AGEs) rather than of advanced lipoxidation end products (ALEs)-in type 2 DM patients with EH.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_1617186643794":{"attribute_name":"Publisher","attribute_value_mlt":[{"subitem_publisher":"The Fukushima Society of Medical Science","subitem_publisher_language":"en"}]},"item_1617186702042":{"attribute_name":"Language","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_1617186920753":{"attribute_name":"Source Identifier","attribute_value_mlt":[{"subitem_source_identifier":"0016-2590","subitem_source_identifier_type":"PISSN"},{"subitem_source_identifier":"2185-4610","subitem_source_identifier_type":"EISSN"},{"subitem_source_identifier":"AA0065246X","subitem_source_identifier_type":"NCID"}]},"item_1617187056579":{"attribute_name":"Bibliographic Information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"75","bibliographicPageStart":"69","bibliographicVolumeNumber":"59","bibliographic_titles":[{"bibliographic_title":"Fukushima Journal of Medical Science","bibliographic_titleLang":"en"}]}]},"item_1617258105262":{"attribute_name":"Resource Type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_1617265215918":{"attribute_name":"Version Type","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_1617353299429":{"attribute_name":"Relation","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.5387/fms.59.69","subitem_relation_type_select":"DOI"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"24500381","subitem_relation_type_select":"PMID"}},{"subitem_relation_type_id":{"subitem_relation_type_id_text":"2015033198","subitem_relation_type_select":"ICHUSHI"}}]},"item_1617605131499":{"attribute_name":"File","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2014-03-20"}],"displaytype":"detail","filename":"FksmJMedSci_59_p69.pdf","filesize":[{"value":"364.2 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://fmu.repo.nii.ac.jp/record/2001839/files/FksmJMedSci_59_p69.pdf"},"version_id":"96850650-84dc-4bce-bec2-d6d9d3695a2a"}]},"item_title":"Suppression of advanced glycation and lipoxidation end products by Angiotensin ii type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension","item_type_id":"40002","owner":"8","path":["1732873412714"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2014-03-20"},"publish_date":"2014-03-20","publish_status":"0","recid":"2001839","relation_version_is_last":true,"title":["Suppression of advanced glycation and lipoxidation end products by Angiotensin ii type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension"],"weko_creator_id":"8","weko_shared_id":-1},"updated":"2024-11-29T09:55:36.467369+00:00"}